Form 4: X4 Pharmaceuticals Director Receives 45,000 Restricted Stock Units

David W J McGirr, a director of X4 Pharmaceuticals, Inc., was granted 45,000 restricted stock units as an annual award for board service.

Summary

• On June 10, 2024, David W J McGirr, a director of X4 Pharmaceuticals, Inc., acquired 45,000 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs were granted as an annual award for his service on the Board of Directors.
• The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date.
• The RSUs will also vest in full upon the occurrence of a change in control of the Issuer.
• Following this transaction, McGirr beneficially owns 96,667 shares of X4 Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It's a neutral event with a slightly positive implication for corporate governance.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The vesting of the RSUs is contingent upon continued board service or a change in control of the Issuer.

Industry Context

Grants of restricted stock units to board members are a common practice to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across the pharmaceutical industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options and restricted stock units as part of their director compensation packages.
• The size of the grant is typical for a company of X4 Pharmaceuticals' size and stage of development.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the director's interests with the company's long-term success.
• The vesting schedule incentivizes the director to remain engaged and contribute to the company's growth.

Key Dates